Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Gloria Searson has been fighting to end the epidemic in New York City for almost 25 years.
Harvoni (ledipasvir/sofosbuvir) is proving highly successful at treating hepatitis C among people coinfected with HIV and genotype 1 of hep C...
HIV-negative men who have sex with men (MSM) are apparently at risk for sexual acquisition of hepatitis C.
Truvada as pre-exposure prophylaxis (PrEP) against HIV takes an estimated week to reach full efficacy and may protect for nearly a week...
The Sovaldi/ledipasvir combination pill to treat hepatitis C does not have a clinically significant impact on five common HIV antiretrovirals.
Very early treatment can help suppress the development of the viral reservoir in monkeys infected with SIV, HIV’s simian cousin.
The cost to treat HIV-positive people with second- and third-line antiretrovirals jumps by a respective 24 and 41 percent compared with...
The rates of liver cancer in the United States more than doubled between 1990 and 2010 while deaths resulting from cirrhosis jumped 43 percent...
One in 13 HIV-positive gay men who maintain an undetectable blood viral load still experience intermittent viral shedding in their semen.
HIV-negative gay men are much less likely to engage in unprotected intercourse if they perceive him to have a detectable viral load.
American and Canadians with treated HIV enjoyed an increase in life expectancy of 15 years between periods of 2000 to 2002 and 2006 to 2007.
Pooled evidence shows that treating HIV when CD4 cells are at or above 350 is beneficial when compared with beginning therapy between 200 and...
Recent dire estimates about the HIV “treatment cascade” may not be as great as previously suspected.
An intravaginal ring infused with the HIV antiretroviral tenofovir protected six out of six macaque monkeys from repeated exposures to...
Forty-two percent of people with HIV in care are regular smokers, a rate twice that of the general population.
A long-acting, injectable version of the antiretroviral dolutegravir prevented rectal transmission of simian HIV (SHIV) in eight macaques.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.